EUVIMEDEUVIMED entdecken
Crossref

Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer

Mizuki Yamazaki, Nao Komizo, Hirotoshi Iihara, Chiemi Hirose, Komei Yanase, Yuto Yamada, Junki Endo, Shuji Yamashita, Yasushi Ohno, Kenichiro Todoroki, Akio Suzuki, Hideki Hayashi

Anticancer Research · 2023-02 · 43 (2) · 725-732

DOI: 10.21873/anticanres.16211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 25.01.2023. Verfasst von Mizuki Yamazaki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University, Gifu, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansProspective StudiesEast Asian PeopleProtein Kinase InhibitorsAniline CompoundsMutationErbB ReceptorsAdenosine TriphosphateAcrylamidesIndolesPyrimidines

Stichwörter der Autor:innen

Genetic polymorphismnon-small cell lung cancerosimertinibpharmacokinetics

Substanzen

Protein Kinase InhibitorsAniline CompoundsErbB ReceptorsAdenosine TriphosphateosimertinibAcrylamidesIndolesPyrimidines

Autor:innen und Institutionen

  • Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
  • Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
  • Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, Gifu, Japan.
  • Department of Cardiology and Respirology Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Laboratory of Analytical and Bio-Analytical Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.

Zitieren

APA

Yamazaki, M., Komizo, N., Iihara, H., Hirose, C., Yanase, K., Yamada, Y., Endo, J., Yamashita, S., Ohno, Y., Todoroki, K., Suzuki, A., & Hayashi, H. (2023). Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer. Anticancer Research, 43(2), 725-732. https://doi.org/10.21873/anticanres.16211

Vancouver

Yamazaki M, Komizo N, Iihara H, Hirose C, Yanase K, Yamada Y, et al. Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer. Anticancer Research. 2023;43(2):725-732. doi:10.21873/anticanres.16211

BibTeX
@article{Yamazaki2023,
  author = {Yamazaki, Mizuki and Komizo, Nao and Iihara, Hirotoshi and Hirose, Chiemi and Yanase, Komei and Yamada, Yuto and Endo, Junki and Yamashita, Shuji and Ohno, Yasushi and Todoroki, Kenichiro and Suzuki, Akio and Hayashi, Hideki},
  title = {Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer},
  journal = {Anticancer Research},
  year = {2023},
  volume = {43},
  number = {2},
  pages = {725--732},
  doi = {10.21873/anticanres.16211}
}
Kostenlos starten →